CMPX · Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Market Cap
123.9M
52 Wk Range
$0.57 - $6.88
Previous Close
$0.68
Open
$0.67
Volume
1,823,734
Day Range
$0.64 - $0.73
Enterprise Value
-31.63M
Cash
163.1M
Avg Qtr Burn
-16.32M
Insider Ownership
12.47%
Institutional Own.
85.75%
Qtr Updated
Sep 30th 2026
